ABSTRACT
INTRODUCTION Lung cancer remains one of the most lethal and frequent malignancies in the world.1 After diagnosis, most patients with both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) still succumb to their disease. Nevertheless, the rate of survival has been increased, although slowly. Increasingly, it has been realized that even in the metastatic setting, long-term survivorship in selected patients with a few brain-or adrenal metastases may be achieved with radical systemic and local treatment.2 In SCLC, the integration of chemotherapy and thoracic radiotherapy has been elucidated and prophylactic cranial irradiation (PCI) has shown to prolong survival in patients with extensive disease (ED) SCLC.
